Literature DB >> 22226094

Clinical applications for biomarkers of acute and chronic graft-versus-host disease.

John E Levine1, Sophie Paczesny, Stefanie Sarantopoulos.   

Abstract

Acute and chronic graft-versus-host disease (aGVHD, cGVHD) are serious complications of allogeneic hematopoietic cell transplantation. The complex pathophysiology of these disease processes is associated with immune system activation, the release of cytokines and chemokines, and alterations in cell populations. The blood levels of specific protein and cellular levels in patients with GVHD have correlated with the development, diagnosis, and prognosis of GVHD. Here, we review the most promising biomarkers for aGVHD and cGVHD with clinical relevance. The utility of GVHD biomarkers in clinical care of allogeneic hematopoietic cell transplantation recipients needs to be proven through clinical trials, and potential approaches to trial design are discussed.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22226094      PMCID： PMC3282925          DOI： 10.1016/j.bbmt.2011.10.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  68 in total

Review 1.  Proteomics techniques and their application to hematology.

Authors:  Ileana M Cristea; Simon J Gaskell; Anthony D Whetton
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

2.  Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS.

Authors:  Vitor Faca; Marc Coram; Doug Phanstiel; Veronika Glukhova; Qing Zhang; Matthew Fitzgibbon; Martin McIntosh; Samir Hanash
Journal:  J Proteome Res       Date:  2006-08       Impact factor: 4.466

Review 3.  Space, selection, and surveillance: setting boundaries with BLyS.

Authors:  Juli P Miller; Jason E Stadanlick; Michael P Cancro
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

4.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.

Authors:  E Holler; H J Kolb; A Möller; J Kempeni; S Liesenfeld; H Pechumer; W Lehmacher; G Ruckdeschel; B Gleixner; C Riedner
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

5.  Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations.

Authors:  Chunyan Zhang; Ivan Todorov; Zhifang Zhang; Yinping Liu; Fouad Kandeel; Stephen Forman; Samuel Strober; Defu Zeng
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

6.  Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

Authors:  Kirk R Schultz; David B Miklos; Daniel Fowler; Ken Cooke; Judith Shizuru; Emmanuel Zorn; Ernst Holler; James Ferrara; Howard Shulman; Stephanie J Lee; Paul Martin; Alexandra H Filipovich; Mary E D Flowers; Daniel Weisdorf; Daniel Couriel; Peter A Lachenbruch; Barbara Mittleman; Georgia B Vogelsang; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

Review 7.  The challenges of modeling mammalian biocomplexity.

Authors:  Jeremy K Nicholson; Elaine Holmes; John C Lindon; Ian D Wilson
Journal:  Nat Biotechnol       Date:  2004-10       Impact factor: 54.908

8.  The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.

Authors:  Francesca Patriarca; Cristina Skert; Alessandra Sperotto; Francesco Zaja; Edmondo Falleti; Rosalba Mestroni; Francesca Kikic; Elisabetta Calistri; Carla Filì; Antonella Geromin; Michela Cerno; Renato Fanin
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

9.  Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation.

Authors:  Jeane Eliete Laguila Visentainer; Sofia Rocha Lieber; Lígia Beatriz Lopes Persoli; Afonso Celso Vigorito; Francisco José Penteado Aranha; Kátia Aparecida de Brito Eid; Gislaine Borba Oliveira; Eliana Cristina Martins Miranda; Cármino Antonio de Souza
Journal:  Exp Hematol       Date:  2003-11       Impact factor: 3.084

10.  Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.

Authors:  Emmanuel Zorn; David B Miklos; Blair H Floyd; Alex Mattes-Ritz; Luxuan Guo; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307
View more
  22 in total

Review 1.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

2.  Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation.

Authors:  Hidekazu Itamura; Takero Shindo; Satoshi Yoshioka; Takayuki Ishikawa; Shinya Kimura
Journal:  Blood Adv       Date:  2020-02-25

Review 3.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

4.  Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Authors:  D M Ponce; A Gonzales; M Lubin; H Castro-Malaspina; S Giralt; J D Goldberg; A M Hanash; A Jakubowski; R Jenq; E B Papadopoulos; M A Perales; M R M van den Brink; J W Young; F Boulad; R J O'Reilly; S Prockop; T N Small; A Scaradavou; N A Kernan; C E Stevens; J N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

Review 5.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

6.  Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

Authors:  Ryan H Moy; Austin P Huffman; Lee P Richman; Lisa Crisalli; Ximi K Wang; James A Hoxie; Rosemarie Mick; Stephen G Emerson; Yi Zhang; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

7.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

8.  Extracellular vesicles as potential biomarkers of acute graft-vs-host disease.

Authors:  G Lia; L Brunello; S Bruno; A Carpanetto; P Omedè; M Festuccia; L Tosti; E Maffini; L Giaccone; M Arpinati; G Ciccone; M Boccadoro; A Evangelista; G Camussi; B Bruno
Journal:  Leukemia       Date:  2017-08-30       Impact factor: 11.528

Review 9.  Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.

Authors:  J W Mays; H Fassil; D A Edwards; S Z Pavletic; C W Bassim
Journal:  Oral Dis       Date:  2012-10-28       Impact factor: 3.511

10.  Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Erin Gatza; Thomas Braun; John E Levine; James L M Ferrara; Shuang Zhao; Tianyi Wang; Lawrence Chang; Andrew Harris; Attaphol Pawarode; Carrie Kitko; John M Magenau; Gregory A Yanik; Daniel R Couriel; Steven Goldstein; James Connelly; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.